{
    "organizations": [],
    "uuid": "d001df73228f7d14eff2613046fc0e698f27d4f9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-antares-pharma-says-fda-accepts-re/brief-antares-pharma-says-fda-accepts-resubmission-to-crl-for-xyosted-nda-idUSB8N1PJ007",
    "ord_in_thread": 0,
    "title": "BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 5 (Reuters) - Antares Pharma Inc:\n* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION\n* FDA CONSIDERED RESUBMISSION A COMPLETE, CLASS 2 RESPONSE & HAS ASSIGNED USER FEE GOAL DATE OF SEPT. 29, 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-05T20:28:00.000+03:00",
    "crawled": "2018-04-06T21:46:51.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "antares",
        "pharma",
        "inc",
        "announced",
        "fda",
        "acknowledged",
        "receipt",
        "resubmission",
        "crl",
        "received",
        "connection",
        "xyosted",
        "new",
        "drug",
        "application",
        "fda",
        "considered",
        "resubmission",
        "complete",
        "class",
        "response",
        "assigned",
        "user",
        "fee",
        "goal",
        "date",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}